DK0842161T3 - 4,5-diaryl-oxazol-derivater - Google Patents

4,5-diaryl-oxazol-derivater

Info

Publication number
DK0842161T3
DK0842161T3 DK96924137T DK96924137T DK0842161T3 DK 0842161 T3 DK0842161 T3 DK 0842161T3 DK 96924137 T DK96924137 T DK 96924137T DK 96924137 T DK96924137 T DK 96924137T DK 0842161 T3 DK0842161 T3 DK 0842161T3
Authority
DK
Denmark
Prior art keywords
oxazole derivatives
carboxy
diaryl oxazole
diaryl
alkylphenyl
Prior art date
Application number
DK96924137T
Other languages
Danish (da)
English (en)
Inventor
Kiyoshi Taniguchi
Kouji Hattori
Kazunori Tsubaki
Osamu Okitsu
Seiichiro Tabuchi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515085.0A external-priority patent/GB9515085D0/en
Priority claimed from AUPN9002A external-priority patent/AUPN900296A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of DK0842161T3 publication Critical patent/DK0842161T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK96924137T 1995-07-21 1996-07-18 4,5-diaryl-oxazol-derivater DK0842161T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9515085.0A GB9515085D0 (en) 1995-07-21 1995-07-21 Heterocyclic compounds
AUPN9002A AUPN900296A0 (en) 1996-03-29 1996-03-29 Heterocyclic compounds
PCT/JP1996/001996 WO1997003973A1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives

Publications (1)

Publication Number Publication Date
DK0842161T3 true DK0842161T3 (da) 2003-01-27

Family

ID=25645150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924137T DK0842161T3 (da) 1995-07-21 1996-07-18 4,5-diaryl-oxazol-derivater

Country Status (17)

Country Link
US (2) US5972965A (es)
EP (2) EP0842161B1 (es)
JP (1) JPH11509191A (es)
KR (1) KR19990063582A (es)
CN (1) CN1095839C (es)
AT (1) ATE224380T1 (es)
AU (1) AU716304B2 (es)
CA (1) CA2227442A1 (es)
DE (1) DE69623785T2 (es)
DK (1) DK0842161T3 (es)
EA (1) EA002156B1 (es)
ES (1) ES2181902T3 (es)
HU (1) HUP9900881A3 (es)
MX (1) MX9800577A (es)
PT (1) PT842161E (es)
TW (1) TW401408B (es)
WO (1) WO1997003973A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
GB9804426D0 (en) * 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
WO2000078350A1 (fr) * 1999-06-21 2000-12-28 Fujisawa Pharmaceutical Co., Ltd. Medicaments destines a un ulcere cutane
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
JPWO2002085412A1 (ja) * 2001-04-18 2004-08-05 藤沢薬品工業株式会社 組織線維化抑制剤
CA2446924C (en) 2001-04-19 2011-02-08 Eisai Co., Ltd. 2-iminopyrrolidine derivatives
IL163866A0 (en) * 2002-03-05 2005-12-18 Ono Pharmaceutical Co 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
MXPA04009243A (es) 2002-04-12 2005-06-08 Pfizer Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
JPWO2004069824A1 (ja) 2003-02-07 2006-05-25 第一製薬株式会社 ピラゾール誘導体
AU2004218187C1 (en) 2003-02-19 2011-04-07 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
DK2343292T3 (da) 2008-09-10 2014-11-03 Asahi Glass Co Ltd Nyt prostaglandin 12-derivat
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
MX2012010483A (es) * 2010-03-08 2012-10-09 Kaken Pharma Co Ltd Agonista novedoso de ep4.
AU2011291614B2 (en) * 2010-08-20 2016-05-26 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2888253A4 (en) * 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC MODULATORS OF HIF FACTOR ACTIVITY USED FOR THE TREATMENT OF DISEASES
HUE040025T2 (hu) 2012-08-24 2019-02-28 Univ Texas A HIF aktivitás heterociklusos modulátorai betegség kezelésére
WO2014031928A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US9663504B2 (en) 2014-02-25 2017-05-30 Board Of Regents, The University Of Texas System Salts of heterocyclic modulators of HIF activity for treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
AU686286B2 (en) * 1993-12-20 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole derivatives
AU688871B2 (en) 1994-03-10 1998-03-19 Astellas Pharma Inc. Naphthalene derivatives as prostaglandin I2 agonists

Also Published As

Publication number Publication date
EP1213285A2 (en) 2002-06-12
WO1997003973A1 (en) 1997-02-06
US5972965A (en) 1999-10-26
TW401408B (en) 2000-08-11
HUP9900881A2 (hu) 1999-08-30
DE69623785T2 (de) 2003-08-07
PT842161E (pt) 2003-02-28
EP1213285A3 (en) 2002-07-03
KR19990063582A (ko) 1999-07-26
HUP9900881A3 (en) 2000-09-28
EA002156B1 (ru) 2001-12-24
DE69623785D1 (de) 2002-10-24
EP0842161B1 (en) 2002-09-18
AU6469796A (en) 1997-02-18
ES2181902T3 (es) 2003-03-01
MX9800577A (es) 1998-04-30
CN1196726A (zh) 1998-10-21
EP0842161A1 (en) 1998-05-20
CN1095839C (zh) 2002-12-11
US6300344B1 (en) 2001-10-09
EA199800141A1 (ru) 1998-08-27
ATE224380T1 (de) 2002-10-15
CA2227442A1 (en) 1997-02-06
JPH11509191A (ja) 1999-08-17
AU716304B2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
DK0842161T3 (da) 4,5-diaryl-oxazol-derivater
NO911231L (no) Fremgangsmaate for fremstilling av 3,5-di-tert. butyl-4-hydroksyfenylmetylen-derivater av 2-substituerte tiazolidinoner, oksazolidinoner og imidazolidinoner.
FI924397A0 (fi) Substituerade pyrimidiner.
DE69108138D1 (de) Imidazopyridinderivate und ihre Verwendung.
NO180407C (no) Anvendelse av 1,3-oksatiolannukleosidanaloger ved fremstilling av et medikament for behandling av hepatitt B
DE69413274D1 (de) Chinoloncarbonsäurederivate, ihre Herstellung und ihre Verwendung als Zelladhäsion Inhibitoren
ES2078509T3 (es) Composiciones inhibidoras de la reaccion de maillard.
DK0444659T3 (da) Farmaceutisk opløsning indeholdende derivater af FK 506
ES2093041T3 (es) Derivados de 2-oxo-(1,8-naftiridina).
DE69406323D1 (de) Substituierte Aminsäure Derivate verwendbar für die Behandlung von Arteriosclerosis
PT916651E (pt) DERIVADOS DE áCIDO FENILALQUILCARBOXILICO
FI883584A (fi) Foerfarande foer framstaellning av 2'-deoxi-5-fluorouridins derivat.
FI913506A0 (fi) Foerfarande foer framstaellning av 6-(substituerat aminopropionyl)-derivat av forskolin.
FI910511A0 (fi) Foerfarande foer framstaellning av substituerade b-diketoner.
ITMI920082A1 (it) Derivati solforati di acidi biliari
DK0534655T3 (da) Thiazolidin-2,4-dioner til behandling af hypertension
NO306302B1 (no) FremgangsmÕte for fremstilling av krystallinsk loracarbef-monohydrat
ATE125790T1 (de) N-fumaramidsäurederivate und diese enthaltende fungizide.